US EditionPublished • loading... • Updated
Tezepelumab, Approved in the European Union for Chronic Rhinosinusitis with Nasal Polyposis
Summary by economiadigital.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The Objective | Periodismo ethosReposted by 
economiadigital.es
economiadigital.esTezspire (tezepelumab), from AstraZeneca and Amgen, has been approved by the European Commission (EC) as a complementary treatment for intranasal corticosteroids in adults with severe chronic rhinosinusitis with nasal polyposis (RSCcPN) that do not respond adequately to standard therapy. The decision is based on the positive results of the phase III WAYPOINT clinical trial, presented at the joint congress of the American Academy of Allergy, Asth…
·Madrid, Spain
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
